^
1d
New P4 trial
|
CRP (C-reactive protein)
|
AiSuDa (ivarmacitinib)
5d
ACT001 synergizes with temozolomide-based chemoradiotherapy to cure refractory glioblastoma by targeting TNF-CXCL10-CD8+ T-cell immunity. (PubMed, Front Pharmacol)
Pharmacological inhibition of the TNF signaling pathway with R-7050 completely abolished the synergistic efficacy of RT/TMZ/ACT001. Taken together, our results demonstrate that ACT001 combined with RT/TMZ can overcome the immunosuppressive barrier of GBM to achieve immune cure in GBM via TNF-CXCL10-CD8+ signaling, strongly suggesting the priority of combining ACT001 with RT/TMZ rather than with αPD-1 in clinical trials.
Journal
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
|
temozolomide • dimethylamino micheliolide (ACT001)
13d
JAK2/STAT3-dependent regulation of MDM4/MDM2-p53 signaling in methotrexate-induced ferroptosis and nephrotoxicity. (PubMed, Arch Pharm Res)
Importantly, either the knockdown of MDM4 or pharmacological inhibition of JAK2/STAT3 signaling pathway with JSI-124 partially attenuated MTX-induced ferroptosis, improved renal function indicators, and attenuated histopathological damage in vivo. Our findings demonstrate that MTX mediates phosphorylation-dependent activation of the JAK2/STAT3 pathway, which facilitates MDM4/MDM2 interaction to induce ferroptosis-associated nephrotoxicity. These findings support a role for JAK2/STAT3-MDM4/MDM2 signaling in MTX-induced ferroptosis and suggest that targeted inhibition of this axis may represent a potential nephroprotective strategy.
Journal
|
JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MDM4 (The mouse double minute 4)
|
methotrexate • cucurbitacin I (JSI-124)
1m
A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation (clinicaltrials.gov)
P1/2, N=32, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
New P1/2 trial
|
AiSuDa (ivarmacitinib)
1m
PEMDA-HN: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (clinicaltrials.gov)
P2, N=69, Terminated, Flamingo Therapeutics NV | Trial completion date: May 2026 --> Aug 2025 | Recruiting --> Terminated; Interim analysis was negative
Trial completion date • Trial termination
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • danvatirsen (AZD9150)
1m
New P4 trial
|
prednisone • AiSuDa (ivarmacitinib)
1m
FUBP3-Mediated Recruitment of STAT3 Complex Formation to Activate EMT Factor Twist1 and Promote Lung Cancer Metastasis. (PubMed, Front Biosci (Landmark Ed))
This study reveals the critical role of FUBP3 in lung cancer metastasis and identifies a new regulatory axis involving FUBP3-STAT3-Twist1. FUBP3 interacts with STAT3, enhancing STAT3-dependent Twist1 expression, which promotes EMT and metastasis. FUBP3 functions as a prognostic biomarker, and STAT3 inhibitors present therapeutic strategies for lung cancer, offering novel insights for precision treatment.
Journal
|
CDH1 (Cadherin 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • VIM (Vimentin) • TWIST1 (Twist Family BHLH Transcription Factor 1)
|
GLG-302
1m
Canonical and noncanonical NF-κB signaling in uveal melanoma: mechanisms, microenvironment, and therapeutic modulation. (PubMed, Med Hypothesis Discov Innov Ophthalmol)
Canonical NF-κB signaling is mechanistically related to UM cell survival, proliferation, and migration, as shown by pharmacologic inhibition like BAY11-7082, and niclosamide and genetic modulation like microRNA-9. NF-κB signaling, particularly the canonical branch, is required for UM malignancy, while noncanonical signaling is linked with high-risk features. Branch-specific genetic manipulations and clinically relevant models should be employed in future research to maximize therapeutic strategies.
Review • Journal
|
BAP1 (BRCA1 Associated Protein 1) • TNFA (Tumor Necrosis Factor-Alpha)
|
niclosamide • Bay11-7082
1m
IRS2 as a driver and therapeutic target in brain metastases from colorectal cancer: a systematic review of mechanistic and translational evidence. (PubMed, Clin Transl Oncol)
IRS2 amplification represents a recurrent but non-universal molecular alteration enriched in a subset of colorectal cancer brain metastases, with mechanistic links to β-catenin signaling and mitochondrial metabolism. Preclinical inhibition of IRS2/IRS1-2 demonstrates translational promise, positioning IRS2 as a context-dependent vulnerability and potential therapeutic target in selected CRC brain-metastatic tumors.
Review • Journal
|
IRS2 (Insulin receptor substrate 2)
|
5-fluorouracil • NT219
1m
Bone marrow tyrosine kinase on chromosome X promotes epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in colorectal cancer. (PubMed, Int J Biol Macromol)
Critically, the STAT3 inhibitor S3I-201 abrogated the pro-tumorigenic effects of BMX overexpression on HT29 cell proliferation, migration, and invasion. In conclusion, our findings establish that BMX drives CRC progression by activating STAT3 signaling pathway, which subsequently suppresses E-cadherin expression to induce EMT.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • BMX (BMX Non-Receptor Tyrosine Kinase)
|
GLG-302
2ms
Melatonin Promotes Neurogenesis via the JAK2/STAT3 Pathway in Hypoxic-Ischemic Neonatal Rats. (PubMed, Neurochem Res)
In addition, the use of a JAK2 inhibitor (WP1066) and agonist (C-A1) verified that Mel exerted its protective effects by down-regulating the JAK2/STAT3 pathway. Morris water maze further confirmed that Mel improved spatial learning and memory function in neonatal rats with HIBD. Multimodal MRI offers a visual basis for monitoring metabolic changes and therapeutic effects, while Mel enhances neurogenesis and mitigates brain injury through inhibition of the JAK2/STAT3 pathway, thus providing a theoretical basis for the clinical application of Mel in HIBD in neonates.
Preclinical • Journal
|
NES (Nestin)
|
WP1066
2ms
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo (clinicaltrials.gov)
P2, N=176, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
AiSuDa (ivarmacitinib)